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Abstract Coronary angioscopy is a useful tool for understanding plaque character-
istics through the plaque color and surface thrombus formation. We experienced an
interesting case of a newly developed yellow neointima 400 days after a sirolimus-
eluting stent implantation. A 72-year-old woman suffering from angina pectoris was
admitted to our hospital. Coronary angiography revealed severe stenosis at the prox-
imal left descending artery and she was implanted with a sirolimus-eluting stent.
Coronary angioscopic observation immediately after stent implantation revealed the
presence of yellow plaque only at the most severe stenosis lesion in the stent place-
ment site. We performed a coronary angiography 400 days after the sirolimus-eluting
stent implantation and did not ﬁnd an in-stent restenosis. An intravascular ultra-
sound indicated minimum neointimal formation. By coronary angioscopy, we could
clearly observe that the neointima had covered the surface of the stent struts; the
stent struts were barely visible under the neointima. Surprisingly, neointima formed
in response to the sirolimus-eluting stent was entirely yellow. Precise mechanisms of
producing yellow neointima was unknown, we may observe a pathologic neointima
induced by sirolimus-eluting stent.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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aneous coronary intervention (PCI) as in-stent
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restenosis has almost been resolved. This is because
the restenosis rate caused by a drug-eluting stent
has been found to be below 10% [1—3]. How-
ever, a new problem has arisen due to the use of
drug-eluting stents. Late stent thrombosis, a life-
threatening complication, has emerged as a major
safety concern [4]. Virmani et al. [5] reported that
the late stent thrombosis could be caused by a
localized hypersensitivity vasculitis that is induced
by remnant stent polymer. It is thought to be difﬁ-
cult to detect such an inﬂammatory response at a
stent implanted site in living patients.
Coronary angioscopy (CAS) is available in Japan;
using this modality may enable the detection
of plaque pathological response after sirolimus-
eluting stent (SES) implantation in living patients
[6]. In this paper, we report an interesting case
of a newly developed yellow neointima at the
stent implanted site 1 year after a SES placement
observed by CAS.
Case report
A 72-year-old woman, who was suspected to be
suffering from angina pectoris, was admitted to
our hospital. Subsequent coronary angiography
(CAG) revealed a severe stenosis at the proximal
left descending artery (black arrow in Fig. 1A).
One week after the administration of aspirin
(100mg/day) and ticlopidine (200mg/day), a SES
(CypherTM; Johnson & Johnson, Tokyo, Japan, diam-
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Fig. 1 Coronary angiograms obtained in LAO 45◦ and CAUD 30◦
at the proximal left descending artery was observed (black a
implantation. (C) Obtained 400 days after intervention; no in-s
designated by the black arrowheads with numbers correspondH. Kawakami et al.
ter: 3mm; length: 28mm) was implanted at the
roximal left descending artery (Fig. 1B). Immedi-
tely after SES implantation, we performed a CAS
y using the FT-203 (Fibertech, Tokyo, Japan) angio-
cope and the AS-003 (Fibertech, Tokyo, Japan)
ptic ﬁber. The angioscopic observation revealed
hat plaque color of the distal to middle por-
ions of the SES were white (Fig. 2D1 and D2),
he proximal portion, which was the most severe
tenosis site, was yellow (Fig. 2D3), and the prox-
mal edge of the SES was white with red thrombus
black arrow in Fig. 2D4). After the procedure,
he was relieved from the effort angina. In order
o observe the SES patency, we performed the
AG 400 days after the SES implantation under
dministration of dual antiplatelet therapy. We
id not ﬁnd any angiographic in-stent restenosis
Fig. 1C). An intravascular ultrasound (IVUS) indi-
ated minimum neointimal formation (white arrows
n Fig. 2E). A CAS revealed that the neointima had
overed the surface of the stent struts; the stent
truts were not distinctly visible under the neoin-
ima (black arrows in Fig. 2F). Surprisingly, the
eointima response to the SES was completely yel-
ow.iscussion
his is the ﬁrst report of yellow neointimal coverage
n the surface of the stent struts observed by CAS
fter SES implantation in a living patient.
projections. (A) Prior to a intervention, a severe stenosis
rrow). (B) Immediately following sirolimus-eluting stent
tent restenosis was observed. In (B) and (C), the portions
to the images in Fig. 2.
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Fig. 2 (D) Coronary angioscopic images immediately after the implantation of the sirolimus-eluting stent. Plaque of
the distal to middle portions of the sirolimus-eluting stent was white in color (D1 and D2); the proximal portion was
yellow (D3); and the proximal edge was white with a red thrombus (black arrow in D4). (E) Intravascular ultrasound
images that were taken 400 days after sirolimus-eluting stent implantation. Neointimal formation covering the surfaces
of the stent struts was observed (white arrows). (F) Coronary angioscopic images taken 400 days after sirolimus-eluting
stent implantation. We could clearly observe that the neointima had covered the surface of the stent struts. The stent
struts were not distinctly visible under the neointima (black arrows). The entire neointima produced in response to
t as de
i
e
b
s
b
s
c
p
i
ﬁ
w
f
p
S
P
t
c
w
o
b
i
o
t
t
i
m
f
a
N
c
s
s
i
a
a
s
p
b
ahe sirolimus-eluting stent was yellow; the yellow color w
mplantation.
Recently, the paradigm of atherosclerotic dis-
ases is shifting from vessel dilation to plaque sta-
ilization. Pharmacological intervention by strong
tatin therapy and mechanical intervention by using
are metal stents is thought to achieve plaque
tabilization. A CAS clearly reveals the plaque
olor change from yellow to white during the
laque stabilization process [7]. Histological stud-
es have proved that plaque yellow color is denser,
brous cap of the plaque is thinner, while the
hite plaque has a thick ﬁbrous cap [6]. There-
ore, a CAS is a strong tool for detecting the
laque condition. In this report, plaque color after
ES implantation became yellow 400 days after
CI. This is a completely opposite phenomenon to
hat after bare metal stent implantation. The pre-
ise mechanism of changing plaque surface color
hite to yellow by SES is still unknown. We may
bserve a part of localized inﬂammation induced
y SES.
Virmani et al. [5] ﬁrst reported a localized
nﬂammation induced by SES in an autopsy case
p
t
s
tnser than that immediately after sirolimus-eluting stent
f a patient with acute myocardial infarction
hat had been caused by SES-induced late stent
hrombosis. They concluded that hypersensitiv-
ty to the remnant polymer is the most likely
echanism and warned that careful long-term
ollow-up of the patients with vessel enlargement
fter SES was necessary. In the RADAR project,
ebeker et al. [8] reported that 17 of the 5783
ases had drug-eluting stent, which included both
irolimus and paclitaxel, had induced a hyper-
ensitivity response and 4 autopsies conﬁrmed an
ntra-stent eosinophilic inﬂammation, thrombosis,
nd an absence of intimal healing. These four
utopsy cases were regarded to be caused by
evere intra-stent vasculitis because all the four
atients passed away due to late stent throm-
osis. Additionally, Finn et al. [9] reported that
SES induces an inﬂammatory cell inﬁltration ateri-struts lesion 3 months after SES implantation
hat persists for 18 months. Latent cases of intra-
tent inﬂammation response to SES are believed
o occur more frequently. However, we could not
[[
[156
detect this phenomenon by CAG or by IVUS. Most
investigators have assessed neointimal formation
in response to SES implantation by using IVUS
[10—12]. Some reports state that optical coher-
ence tomography is more efﬁcient for detecting
a minimum neointimal formation, than IVUS [13].
However, these two modalities can be used to
assess neointimal formation quantitatively, but not
qualitatively. By using a CAS, we can assess the
quality of plaque and neointima by observing the
plaque color and thrombus formation. Therefore,
the detection of a case of latent inﬂammatory
response seems possible by observing the change
in plaque surface color after SES implantation.
We believe that the yellow neointimal formation
after a SES implantation, as observed in this study,
demonstrates one of the SES-induced inﬂammatory
responses.
Two possible mechanisms were speculated to
develop yellow neointima after SES implantation.
One of the mechanisms is vessel inﬂammation
described previously. Virmani et al. reported
extensive inﬂammatory inﬁltrate consisting of
eosinophils, T-lymphocytes, and macrophages after
SES implantation [9]. In the vessel wall with poor
endothelialization, macrophages change to foam
cells under high cholesteremia. Accumulation of
foam cells is thought to look yellow by angioscopy
like fatty streak, early stage of atherosclerosis
[14].
The development of the yellow neointima could
also be caused by remaining ﬁbrin deposition and
the attachment of the organized thrombus to the
stent struts. Histologic ﬁndings 30 days after the
SES implantation revealed persistent peristruts ﬁb-
rin deposition with poor endothelialization [15].
Generally, a freshly formed ﬁbrin-rich thrombus is
white in color, while a mature thrombus is yel-
low in color [14]. Therefore, a major portion of
the yellow neointima may comprise a mature ﬁb-
rin thrombus that was attached around surface of
the stent struts. These two mechanisms were mixed
in the process of developing the yellow neoin-
tima.
Finally, further studies will be needed to be car-
ried out in order to understand the effects of SES
implantation.
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